Alumis Reports Q3 2026 Results, $94.9 Million Net Loss
Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.
How this was made
The 30-second read
Why it matters
The Q3 loss underscores high R&D spend and cash consumption, but the company retains a sizable cash position to fund operations into 2027.
Market read
Quarterly earnings of a micro‑cap biotech provide fresh data for traders; the loss and cash runway are the main drivers.
What to watch
Potential upcoming NDA filing and pipeline progress could offset short‑term cash‑burn concerns.
Background
Alumis is a clinical‑stage biotech focusing on TYK2 inhibitors for dermatology and autoimmune diseases.
Ticker impact
Alumis reported Q3 2026 results with $94.9M net loss and cash runway to Q4 2027.
likely downward pressure as the market prices in higher cash burn and delayed milestones
Quarterly earnings are the primary disclosure; the loss magnitude and cash balance are material for a micro‑cap biotech.
Market effects
Highlights ongoing challenges for early‑stage biotech cash burn and trial risk, may affect peer valuations.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
If the Phase 3 data on envudeucitinib is viewed as a breakthrough, the loss may be seen as a temporary investment in future upside.
Key entities
- companyAlumis Inc.
Clinical‑stage biotech reporting Q3 2026 results.
